Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | PDE5A | O76074 | 17/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PDE2A | O00408 | 1/20 | 0.60 |
| ▸ | PDE9A | O76083 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
| ▸ | PDE6C | P51160 | 1/20 | 0.60 |
| ▸ | PDE1A | P54750 | 1/20 | 0.60 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.60 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004511 | 0.91 | KDM4E (0.68) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL7002595 | 0.88 | KDM4E (0.67) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL7000981 | 0.87 | KDM4E (0.71) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL7003894 | 0.87 | KDM4E (0.63) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL7005470 | 0.86 | KDM4E (0.60) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL7000157 | 0.85 | KDM4E (0.76) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL7006392 | 0.83 | KDM4E (0.75) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL1253 | 0.83 | KMT2A (0.73) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL31202676 | 0.83 | KMT2A (0.73) | KDM4EPDE5AKMT2APDE2APDE9A | |
| SCHEMBL7004870 | 0.82 | PDE5A (0.74) | KDM4EPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716298-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2014-05-06 | — | — | US | claimed |
| EP-2556820-A2 | COMPOSITION CONTAINING PDE5 INHIBITOR FOR RELIEVING SKIN WRINKLES | SK Chemicals, Co., Ltd. (KR) | 2013-02-13 | — | — | EP | claimed |
| US-20130030174-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2013-01-31 | — | — | US | claimed |
| US-6844436-B2 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | DONG A. PHARM. CO., LTD. (KR) | 2005-01-18 | — | — | US | claimed |
| US-20030176696-A1 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | MEZZION PHARMA CO., LTD. (KR) | 2003-09-18 | — | — | US | claimed |
| EP-1129093-B1 | PYRAZOLOPYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF IMPOTENCE | DONG A PHARM CO LTD (KR) | 2003-07-23 | — | — | EP | claimed |
| US-6583147-B1 | 5-(2-ethoxy-5-(isopropylamidosulfonyl)phenyl)-1-methyl-3-propy l- 1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one; | DONG A PHARM CO., LTD. (KR) | 2003-06-24 | — | — | US | claimed |
| US-9155691-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2015-10-13 | — | — | US | disclosed |
| US-20140179701-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| US-8716298-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2014-05-06 | — | — | US | disclosed |
| EP-2556820-A2 | COMPOSITION CONTAINING PDE5 INHIBITOR FOR RELIEVING SKIN WRINKLES | SK Chemicals, Co., Ltd. (KR) | 2013-02-13 | — | — | EP | disclosed |
| US-20130030174-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2013-01-31 | — | — | US | disclosed |
| US-6844436-B2 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | DONG A. PHARM. CO., LTD. (KR) | 2005-01-18 | — | — | US | disclosed |
| US-20030176696-A1 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | MEZZION PHARMA CO., LTD. (KR) | 2003-09-18 | — | — | US | disclosed |
| US-6583147-B1 | 5-(2-ethoxy-5-(isopropylamidosulfonyl)phenyl)-1-methyl-3-propy l- 1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one; | DONG A PHARM CO., LTD. (KR) | 2003-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176696-A1 | Preparing pyrazolopyrimidinone derivatives for the treatment of impotence | PDE3B, PDE8B, PDE5A | KDM4E 2028/4885PDE5A 3/4885KMT2A 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.